No significant differences were observed in β-hexosaminidase or β-galactocerebrosidase activity of GBA-PD MOs compared to unaffected controls, however, an increase in β-galactosidase activity was detected in patient-derived MOs (Supplementary Fig. 3b). This evidence concerns the gene GBA1 and Parkinson disease.